Novel cationic lipid with reduction-responsive cleavable hydrophobic tail for siRNA delivery

doi:10.5246/jcps.2018.06.039

Journal of Chinese Pharmaceutical Sciences ›› 2018, Vol. 27 ›› Issue (6): 383-396.DOI: 10.5246/jcps.2018.06.039

• Original articles • Previous Articles Next Articles

Novel cationic lipid with reduction-responsive cleavable hydrophobic tail for siRNA delivery

Yi Yan¹, Shihe Cui¹, Jing Sun¹, Piaopiao Li¹, Haitao Zhang^1,2, Jiancheng Wang^1*

1. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China

Received:2018-05-06 Revised:2018-05-28 Online:2018-06-30 Published:2018-06-03
Contact: Tel.: +86-010-82805932, E-mail: wang-jc@bjmu.edu.cn
Supported by:
National Natural Science Foundation of China (Grant No. 81473158, 81690264 and 81773650), the New Drug R&D program of China (Grant No. 2018ZX09721003-004) and the Opening Project of Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education (Sichuan University).

Abstract

Abstract:

To achieve a higher transfection efficiency and lower toxicity, a novel herringbone-like cationic lipid (2ssHLL) composed of hydrophilic aspartic acid linked with two reduction-responsive cleavable hydrophobic oleic acid tails was synthesized and assessed in this study. In our results, the cationic nanoplexes with a uniform spherical shape and a particle size of ~150 nm were successfully prepared by the electrostatic interaction between siRNAs and 2ssHLL-based liposomes. From the results evaluated in HepG2 cells, it was shown that the nanoplexes exhibited high cellular uptake of siRNA with a low cytotoxicity. Moreover, the significant down-regulation effects of 2ssHLL/siEGFR nanoplexes on target mRNA were displayed by RT-PCR analysis, which were similar to those of Lipofectamine2000. It suggested that the enhanced siRNA gene silencing efficiency was probably attributed to the detachment of hydrophobic tail chains induced by reduction-responsive cleavage. This mechanism was also confirmed by the changes of size distribution and siRNA release of nanoplexes in the reductive environment and DTT-absence condition. Overall, we believed that the redox-active herringbone-like 2ssHLL would be a potential nanocarrier towards siRNA delivery.

Key words: siRNA delivery, Disulfide bond, Reduction-responsive, Nanoplexes, Cleavage

CLC Number:

R943

Supporting:

Yi Yan, Shihe Cui, Jing Sun, Piaopiao Li, Haitao Zhang, Jiancheng Wang. Novel cationic lipid with reduction-responsive cleavable hydrophobic tail for siRNA delivery[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(6): 383-396.

References

[1] Castanotto, D.; Rossi, J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009, 457, 426-433.

[2] Meister, G.; Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004, 431, 343-349.

[3] Dowdy, S.F. Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 2017, 3, 222-229.

[4] Ozcan, G.; Ozpolat, B.; Coleman, R.L.; Anil, S.; Berestein, G. Preclinical and clinical development of siRNA-based therapeutics. Adv. Drug Delive. Rev. 2015, 87, 108-119.

[5] Zuckerman, J.E.; Davis, M.E. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 2015, 14, 843-856.

[6] Lin, Q.; Chen, J.; Zhang, Z.; Zheng, G. Lipid-based nanoparticles in the systemic delivery of siRNA. Nanomedicine-UK. 2014, 9, 105-120.

[7] Ozpolat, B.; Sood, A.K.; Lopez-Berestein, G. Liposomal siRNA nanocarriers for cancer therapy. Adv. Dru. Delive. Rev. 2014, 66, 110-116.

[8] TsengY, C.; Mozumdar, S.; Huang, L. Lipid-based systemic delivery of siRNA. Adv. Drug Delive. Rev. 2009, 9, 721-731.

[9] Majzoub, R.N.; Ewert, K.K.; Safinya, C.R. Cationic liposome-nucleic acid nanoparticle assemblies with applications in gene delivery and gene silencing. Philos. Transact. Ser. A Math. Phys. Eng. Sci. 2016, 2072, 1-14.

[10] Semple, S.C.; Akinc, A.; Chen, J.; Sandhu, A.P.; Mui, B.L.; Cho, C.K.; Sah, D.W.; Stebbing, D.; Crosley, E.J.; Yaworski, E.D.; Hafez, I.M.; Dorkin, J.R.; Qin, J.; Lam, K.; Rajeev, K.G.; Wong, K.F.; Jeffs, L.B.; Nechev, L.; Eisenhardt, M.L.; Jayaraman, M.; Kazem, M.; Maier, M.A.; Srinivasulu, M.; Weinstein, M.J.; Chen, Q.; Alvarez, R.; Barros, S.A.; De, S.; Klimuk, S.K.; Borland, T.; Kosovrasti,V.; Cantley, W.L.; Tam, Y.K.; Manoharan, M.; Ciufolini, M.A.; Tracy, M.A.; Fougerolles, A.; MacLachlan, I.; Cullis, P.R.; Madden, T.D.; Hope, M.J. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28, 172-178.

[11] Jayaraman, M.; Ansell, S.M.; Mui, B.L.; Tam, Y.K.; Chen, J.X.; Du, X.J.; Butler, D.B.; Eltepu, L.; Matsuda, S.; Narayanannair, J.K.; Rajeev, K.G.; Hafez, I.M.; Akinc, A.; Maier, M.A.; Tracy, M.A.; Cullis, P.R.; Madden, T.D.; Manoharan, M.; Hope, M.J. Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing in vivo. Angew. Chem. Int. Ed. Engl. 2012, 1, 8529-8533.

[12] Zhang, S.; Zhao, B.; Jiang, H.; Wang, B.; Ma, B.C. Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Controlled Release. 2007, 123, 1-10.

[13] Rehman, Z.U.; Zuhorn, I.S.; Hoekstra, D. How cationic lipids transfer nucleic acids into cells and across cellular membranes: Recent advances. J. Controlled Release. 2013, 166, 46-56.

[14] Lv, H.; Zhang, S.; Wang, B.; Cui, S.H.; Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Controlled Release. 2006, 114, 100-109.

[15] Obata, Y.; Tajima, S.; Takeoka, S. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. J. Controlled Release. 2010, 142, 267-276.

[16] Obata, Y.; Suzuki, D.; Takeoka, S. Evaluation of Cationic Assemblies Constructed with Amino Acid Based Lipids for Plasmid DNA Delivery. Bioconjug. Chem. 2008, 19, 1055-1063.

[17] Zheng, Y.; Guo, Y.G.; Li, Y.T.; Wu, Y.; Zhang, L.H.; Yang, Z.J. A novel gemini-like cationic lipid for the efficient delivery of siRNA. New J. Chem. 2014, 38, 4952-4962.

[18] Wang, B.; Yi, W.J.; Zhang, J.; Zhang, Q.F.; Xun, M.M.; Yu, X.Q. TACN-based cationic lipids with amino acid backbone and double tails: materials for non-viral gene delivery. Bioorg Med. Chem. Lett. 2014, 24, 1771-1775.

[19] Ma, X.F.; Sun, J.; Qiu, C.; Wu, Y.F.; Yu, M.Z.; Pei, X.W.; Wei, L.; Niu, Y.J.; Pang, W.H.; Yang, Z.J.; Wang, J.C.; Zhang, Q. The role of disulfide-bridge on the activities of H-shape gemini-like cationic lipid based siRNA delivery. J. Controlled Release. 2016, 235, 99-111.

[20] Breunig, M.; Hozsa, C.; Lungwitz, U.; Kazuo, W.; Umeda, I.; Kato, H.; Goepferich, A. Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: Disulfide bonds boost intracellular release of the cargo. J. Controlled Release. 2008, 130, 57-63.

[21] Darpolor, M.M.; Basu, S.S.; Worth, A.; Nelson, D.; Clarke-Katzengerg, R.H.; Glickson, J.D.; Kaplan, D.E.; Blair, L.A. The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and 13C-isotope based metabolomics. NMR. Biomed. 2014, 27, 381-389.

[22] Sivashanmugam, M.; Umashankar, J.V.; Sulochana, K.N. Ornithine and its role in metabolic diseases: An appraisal. Biomed. Pharmacother. 2017, 86, 185-194.

[23] Hiraishi, T. Poly(aspartic acid) (PAA) hydrolases and PAA biodegradation: current knowledge and impact on applications. Appl. Microbiol. Biotechnol. 2016, 100, 1623-1630.

[24] Son, S.; Ran, N.; Kim, J.; Singha, K.; Kim, W.J. Bioreducible Polymers for Gene Silencing and Delivery. Accounts. Chem. Res. 2012, 45, 1100-1122.

[25] Saito, G.; Swanson, J.A.; Lee, K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Delive. Rev. 2003, 55, 199-215.

[26] Yin, T.; Wang, L.; Yin, L.; Jianpin, Z.; Meirong, H. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. Biomaterials. 2015, 61, 10-25.

[27] Schafer, F.Q.; Buettner, G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Biology & Medicine. 2001, 30, 1191-1210.

[28] Nicholson, R.I.; Gee, J.M.; Harper, M.E. EGFR and cancer prognosis. Eur. J. Cancer. 2001, 37, S9-S15.

[29] Varkouhi, A.K.; Scholte, M.; Storm, G.; Haisma, H. Endosomal escape pathways for delivery of biologicals. J. Controlled Release. 2011, 151, 220-228.

[30] Wattiaux, R.; Laurent, N.; Wattiaux-De, C.S.; Jadot, M. Endosomes, lysosomes: their implication in gene transfer. Adv. Drug Delive. Rev. 2000, 41, 201-208.
[31] Juliano, R.L.; Carver, K. Cellular uptake and intracellular trafficking of oligonucleotides. Adv. Drug Delive. Rev. 2015, 87, 35-45.

Novel cationic lipid with reduction-responsive cleavable hydrophobic tail for siRNA delivery

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments

[1]	Piaopiao Li, Yi Yan, Haitao Zhang, Ru Wang, Huhu Han, Jiancheng Wang. Treatment of cervical cancer by siRNA-loaded chitosan-coated calcium phosphate nanoparticles [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(8): 517-529.
[2]	Yating Li, Yi Zheng, Delin Pan, Bo Xu, Yun Wu^*, Zhenjun Yang, Lihe Zhang . Development of a high-content screening method to evaluate the cellular population-based biological activity of new siRNA delivering reagent [J]. Journal of Chinese Pharmaceutical Sciences, 2013, 22(6): 467-474.
[3]	Fei-Lin Nie, Xiao-Feng Wang, Yang Liu, Zhen-Jun Yang^*, Liang-Ren Zhang, Li-He Zhang. Synthesis of nucleoside-peptide conjugate with disulfide bond as linker at C-5 of uridine [J]. , 2008, 17(3): 203-208.
[4]	Ying Wang, Shu-Cheng Zhang, Jing-Feng Dai, Jin-Song Qiu, Yi Qiu, Yi-Bin Sun. Effect of Pentamidine Isethionate (PI) on Fertilized Ova of ICR Mice [J]. , 1994, 3(1): 66-70.